Novo Nordisk submits obesity drug for FDA approval
Semaglutide will also be used as a treatment for obesity, according to Novo Nordisk's plan – the pharmaceutical giant has submitted an application to the FDA in the US.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Within the next six months, Novo Nordisk will find out whether its drug semaglutide can be used as a treatment for obesity, aside from its use as a drug against diabetes in US patients.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
